{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS%2B&page=82",
    "query": {
      "intervention": "AS+",
      "page": 82
    },
    "page_size": 10
  },
  "pagination": {
    "page": 82,
    "page_size": 10,
    "total_count": 48537,
    "total_pages": 4854,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS%2B&page=83&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS%2B&page=81&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T19:42:39.315Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03386305",
      "title": "Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Post Liver Transplant"
      ],
      "interventions": [
        {
          "name": "EnvarsusXR",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein Healthcare Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 35,
      "start_date": "2017-12-13",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-01-08",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386305"
    },
    {
      "nct_id": "NCT07052305",
      "title": "NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "NT-I7",
          "type": "DRUG"
        },
        {
          "name": "CAR T-cell therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-03-12",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07052305"
    },
    {
      "nct_id": "NCT04827056",
      "title": "Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Use Disorder (AUD)",
        "Post Traumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg",
          "type": "DRUG"
        },
        {
          "name": "Ethanol Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "PTSD Reactivity Condition",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Alcohol Cue Reactivity",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "Pharmacotherapies for Alcohol and Substance Use Disorders Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-11-09",
      "completion_date": "2023-06-02",
      "has_results": false,
      "last_update_posted_date": "2023-10-26",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 1,
      "location_summary": "West Haven, Connecticut",
      "locations": [
        {
          "city": "West Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827056"
    },
    {
      "nct_id": "NCT00370331",
      "title": "RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Purpura, Thrombocytopaenic, Idiopathic"
      ],
      "interventions": [
        {
          "name": "eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2006-11",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2017-04-18",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 26,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 20 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00370331"
    },
    {
      "nct_id": "NCT03035253",
      "title": "A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "OMP-305B83",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoMed Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2016-12",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Denver, Colorado • Fort Collins, Colorado + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03035253"
    },
    {
      "nct_id": "NCT03605537",
      "title": "Use of Mometasone Eluting Stent in Choanal Atresia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Choanal Atresia"
      ],
      "interventions": [
        {
          "name": "Drug-eluting Stent Mometasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "Up to 10 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-07-03",
      "completion_date": "2019-10-11",
      "has_results": false,
      "last_update_posted_date": "2021-04-06",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03605537"
    },
    {
      "nct_id": "NCT05114837",
      "title": "Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma Leukemia"
      ],
      "interventions": [
        {
          "name": "allogeneic CAR19 regulatory T cells (CAR19-tTreg)",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-09",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-19",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05114837"
    },
    {
      "nct_id": "NCT01316237",
      "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "GS-6620",
          "type": "DRUG"
        },
        {
          "name": "GS-6620 tablet, 450 mg BID",
          "type": "DRUG"
        },
        {
          "name": "GS-6620 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 90,
      "start_date": "2011-01",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-03-26",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 12,
      "location_summary": "Anaheim, California • Los Angeles, California • DeLand, Florida + 8 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01316237"
    },
    {
      "nct_id": "NCT04052360",
      "title": "Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Cenerimod",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Innovation GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2019-08-07",
      "completion_date": "2019-11-02",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04052360"
    },
    {
      "nct_id": "NCT02239120",
      "title": "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke",
        "Secondary Prevention"
      ],
      "interventions": [
        {
          "name": "optional ASA as comedication",
          "type": "DRUG"
        },
        {
          "name": "placebo to ASA",
          "type": "DRUG"
        },
        {
          "name": "placebo to optional ASA as comedication",
          "type": "DRUG"
        },
        {
          "name": "placebo to dabigatran etexilate",
          "type": "DRUG"
        },
        {
          "name": "ASA 100 mg",
          "type": "DRUG"
        },
        {
          "name": "dabigatran etexilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "150 Years",
        "sex": "ALL",
        "summary": "18 Years to 150 Years"
      },
      "enrollment_count": 5390,
      "start_date": "2014-11-27",
      "completion_date": "2018-08-14",
      "has_results": true,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-11-11T19:42:39.315Z",
      "location_count": 110,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02239120"
    }
  ]
}